DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

This trial is testing a new drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) — two closely related blood cancers — that have come back after previous treatments or stopped responding to them. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of CLL or SLL that requires treatment - Your cancer has relapsed (come back) or is refractory (not responding to treatment) - Your blood counts and organ function meet minimum safety levels - You are reasonably functional day-to-day (ECOG 0–2) **You may NOT be eligible if...** - Your leukemia has spread to the brain or spinal fluid, or has transformed into a more aggressive lymphoma (Richter transformation) - You recently had a stem cell transplant, gene therapy, or major surgery (within the past 4–12 weeks depending on treatment type) - You take blood thinners (vitamin K antagonists) - You have had certain recent cancer treatments within specified timeframes Talk to your doctor to see if this trial is right for you.